...lentiviral vectors to integrate shRNA constructs into genomic DNA. It was developed by the company’s Dharmacon...

...of 39 million shares in a placing. In July, Horizon said it will purchase the Dharmacon...
...million in cash and $35 million in Horizon stock. The offering closed on Aug. 31. Dharmacon...

...of 39 million shares in a placing. In July, Horizon said it will purchase the Dharmacon...
...General Electric Co. (NYSE:GE) for $50 million in cash and $35 million in Horizon stock. Dharmacon...

...RNAi to create permanent gene silencing in research cell lines. The platform, called Thermo Scientific Dharmacon...

...of technology development at CYTR's Rxi Pharmaceuticals Corp. subsidiary, formerly director of technology development at Dharmacon Inc. WIR...

...FSH's Dharmacon Inc. subsidiary (Lafayette, Co.) partnered with Lentigen to develop and manufacture lentiviral expression reagents for...
...for RNAi research. The deal combines Dharmacon's gene silencing capabilities with Lentigen's LentiMax vector system. Dharmacon...

...FSH's Dharmacon Inc. subsidiary (Lafayette, Colo.) will use its SMARTselection and SMARTpool technologies to optimize siRNAs for...

...The companies will co-promote siRNA libraries from FSH's Dharmacon Inc. subsidiary (Lafayette, Co.) with amaxa's Nucleofector siRNA...

...ALNY granted FSH's Dharmacon Inc. subsidiary (Lafayette, Co.) a non-exclusive license to the Kreutzer-Limmer patents, which cover...
...the Kreutzer-Limmer patents, which cover siRNAs and their use to mediate RNAi in mammalian cells. Dharmacon...

...therapeutics for ophthalmic diseases. The deal combines Dharmacon's RNAi technologies with ACL's ophthalmic disease targets. Dharmacon...